Clinical Trial Update: Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abrocitinib for moderate-to-severe chronic hand eczema refractory to corticosteroids, with updates on efficacy, safety, and tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hand Eczema

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Innovaderm Research Inc. | Conditions: Chronic Hand Eczema | Phase 2 | Status: COMPLETED